Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Soo Yoon

Showing results (1061-1070 of 1,104) with videos related to

Pageof 111
Sort By:
The New England Journal of Medicine|December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaMaría-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Plos One|November 9, 2016
Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic SyndromeKoung Jin Suh, June-Won Cheong, Inho Kim, et al.
Science Advances|February 4, 2020
Nearly room temperature ferromagnetism in a magnetic metal-rich van der Waals metalJunho Seo, Duck Young Kim, Eun Su An, et al.
Leukemia & Lymphoma|June 26, 2020
Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysisGa-Young Song, Sung-Hoon Jung, Je-Jung Lee, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Annals of Hematology|April 6, 2013
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemiaSang Min Lee, Won Sik Lee, Ho Jin Shin, et al.
Pediatric Blood & Cancer|May 20, 2016
Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel ChemotherapyJun Ah Lee, Dae-Geun Jeon, Wan Hyeong Cho, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Clinical Pharmacology and Therapeutics|January 20, 2023
Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 InhibitorsJun-Ichi Nishimura, Antoine Soubret, Noriko Arase, et al.
Blood|January 25, 2020
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuriaAlexander Röth, Jun-Ichi Nishimura, Zsolt Nagy, et al.
Pageof 111

Showing results (1061-1070 of 1,104) with videos related to

Sort By:
Pageof 111
The New England Journal of Medicine|December 13, 2017
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated MyelomaMaría-Victoria Mateos, Meletios A Dimopoulos, Michele Cavo, et al.
Plos One|November 9, 2016
Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic SyndromeKoung Jin Suh, June-Won Cheong, Inho Kim, et al.
Science Advances|February 4, 2020
Nearly room temperature ferromagnetism in a magnetic metal-rich van der Waals metalJunho Seo, Duck Young Kim, Eun Su An, et al.
Leukemia & Lymphoma|June 26, 2020
Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysisGa-Young Song, Sung-Hoon Jung, Je-Jung Lee, et al.
Lancet (London, England)|December 15, 2019
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trialMaria-Victoria Mateos, Michele Cavo, Joan Blade, et al.
Annals of Hematology|April 6, 2013
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemiaSang Min Lee, Won Sik Lee, Ho Jin Shin, et al.
Pediatric Blood & Cancer|May 20, 2016
Higher Gemcitabine Dose Was Associated With Better Outcome of Osteosarcoma Patients Receiving Gemcitabine-Docetaxel ChemotherapyJun Ah Lee, Dae-Geun Jeon, Wan Hyeong Cho, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Clinical Pharmacology and Therapeutics|January 20, 2023
Mitigating Drug-Target-Drug Complexes in Patients With Paroxysmal Nocturnal Hemoglobinuria Who Switch C5 InhibitorsJun-Ichi Nishimura, Antoine Soubret, Noriko Arase, et al.
Blood|January 25, 2020
The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuriaAlexander Röth, Jun-Ichi Nishimura, Zsolt Nagy, et al.
Pageof 111